Theratechnologies Inc T.TH

All comers dose and safety vs targeting high sortlin express

[BlitzBuuckeyeoh]

Should we possibly see much quicker and stronger results? If our concept works!

[SPCEO1]

We now know that the concept behind TH-1902 works at some level due to the three responders as well as Juniper's wife's response. But we do not know if the drug works consistently enough or well enough to move forward in drug trials. It likely will, but that is yet to be proven. We do not yet have all the details about the phase 1a and by the time we get them, they may no longer be even

[Bucknelly21]

Wish i could say im surprised if what you say is the case... but thera could easily make a statement to allow investors to hone in on what they should be focusing on.

[Biobob]

Longer.. and 500k options coming du in dec. 2022..... no liquidity... sucks unless they can do something about the sh..tty stock price...

[SPCEO1]

Somehow, you always overlook the IMMU potential this stock holds - the potential for stratospheric returns if the Sort1+ platform becomes a real thing and it is moving closer to that being a real possibility everyday. It is why those who own it are not selling.  Unless I am missing something, there are only 230,000 additional $0.38 options coming due by 12/20/22. 105,000 left from Lafond and

[Bucknelly21]

879 shares... thera is officially on no ones radar, great work paul, phillippe and elif

[jfm1330]

Two things. They do a trial on a targeted drug, but relying on target probability, not target confirmation. So just that will lower the overall response rate. The second point is that their patients are advanced patients with a high percentage already treated with taxanes and no longer responding to it. So docetaxel resistance, even to the higher intracellular doses TH1902 should allow will be a

[SPCEO1]

Technically, I know you re right about all of this but on the not confirming the sortilin overexpression on the 3 responders, I am not too concerned as it is hard to concieve of how the drug worked if those patients did not overexpress sortilin. I suppose there would be some chance that free docetaxel could be the cause of the beneft, but I think that seems like a low probability too. So,while

[scarlet1967]

      This study is looking at the affinity between drug-delivering nanoparticles and diseased/healthy cells, it really is about precise medicine/technology at molecular level, complicated and unexplored. So they found certain biomarkers can have an important role re that affinity therefore various “heterogeneous” cancers can respond to drugs and others don’t. Also in case of

[LouisW]

Agreed. They have to select the patient according the SORT1 expression level. TH cannot let the propability to determine the fate. Unless they observe almost everyone express high SORT1. Immunomedics didnt select the patient prior to conductig the larger trial since almost all (88%) of the archival tumor samples in paraffin from these patients in earlier trial expressed relatively high

[Bucknelly21]

How can a company think they dont have a serious issue after 314 shares have been traded in over an hour

[Biobob]

Give a 5$ takover and be gone... will slowly go to 1.50$ with it's 2$ target.... Paul you suck big time.

[qwerty22]

They have to do some learning before they do some selecting.

[Biobob]

The learnings are taking to long and the windows for the buying and the sellings like would say Paul are inexistant... 

[qwerty22]

The learnings take long, not too long.  

[LouisW]

We know three responders in does escalation study. I personally want to know what the status of the rest of 15 patients. WHy those 15 patients didnt respond to TH1902? That part is still missing.